Daniela Urina-Jassir
Research Subjects
Daniela Urina-Jassir has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Miguel Urina-Triana
Universidad Simón Bolívar
3 shared publications - Aneesh Dhore-Patil
Wake Forest University, Sanger Heart and Vascular Institute, Atrium Health, Charlotte, North Carolina
2 shared publications Robert C. Hendel
Tulane University School of Medicine
2 shared publications- Thierry H. Le Jemtel
Section of Cardiology, John W. Deming Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, SL-48, New Orleans, LA 70112, USA
2 shared publications Ali Salami
Department of Mathematics, Faculty of Sciences Lebanese University Nabatieh Lebanon
1 shared publicationAnan Abu Rmilah
Department of Cardiology Mayo Clinic Rochester Minnesota USA
1 shared publication
Latest Publications
- 7 July 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (8) , 2041-2060
Predictors of Post‐TAVR Left Bundle Branch Block: A Systematic Review and Meta‐Analysis
Left bundle branch block (LBBB) is the most common conduction abnormality following transcatheter aortic valve replacement (TAVR) and has been associated with adverse clinical outcomes. While multiple predictors of post‐TAVR LBBB have been proposed, data remain limited. This systematic review and meta‐analysis aims to identify and summarize predictors of new‐onset LBBB post‐TAVR. A systematic literature search was performed to identify studies that reported predictors of new‐onset post‐TAVR LBBB. Extracted data included patient factors, electrocardiographic (ECG) and anatomic parameters, and device‐related factors. A random‐effects model was used to calculate crude risk ratios (RRs), mean differences, and 95% confidence intervals (CI) of the predictors. Of 450 articles screened, 17 studies comprising a total of 6357 patients were included. Among these, 26.4% developed post‐TAVR LBBB. Increased risk was associated with diabetes mellitus (RR: 1.22, p < 0.001), use of 29‐mm valve (RR: 1.59, p < 0.001), and use of Medtronic CoreValve (MCV) (RR: 2.25, p = 0.008). Significant differences were found between patients with and without LBBB in interventricular septal thickness (IVS; by −0.66 mm), membranous septal length (MSL; by −0.9 mm), left ventricular outflow tract (LVOT) diameter (by −0.48 mm), PR interval (by +13.95 ms), and prosthesis implantation depth (by +2.6 mm). Diabetes Mellitus, use of 29‐mm valve or MCV, decreased IVS thickness, shorter MSL, smaller LVOT diameter, increased prosthesis implantation depth, and prolonged PR duration were all associated with an elevated risk of post‐TAVR LBBB. Early identification of these predictors may help reduce the risk of conduction abnormalities after TAVR.
- 7 July 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (8) , 2041-2060
Predictors of Post‐TAVR Left Bundle Branch Block: A Systematic Review and Meta‐Analysis
Left bundle branch block (LBBB) is the most common conduction abnormality following transcatheter aortic valve replacement (TAVR) and has been associated with adverse clinical outcomes. While multiple predictors of post‐TAVR LBBB have been proposed, data remain limited. This systematic review and meta‐analysis aims to identify and summarize predictors of new‐onset LBBB post‐TAVR. A systematic literature search was performed to identify studies that reported predictors of new‐onset post‐TAVR LBBB. Extracted data included patient factors, electrocardiographic (ECG) and anatomic parameters, and device‐related factors. A random‐effects model was used to calculate crude risk ratios (RRs), mean differences, and 95% confidence intervals (CI) of the predictors. Of 450 articles screened, 17 studies comprising a total of 6357 patients were included. Among these, 26.4% developed post‐TAVR LBBB. Increased risk was associated with diabetes mellitus (RR: 1.22, p < 0.001), use of 29‐mm valve (RR: 1.59, p < 0.001), and use of Medtronic CoreValve (MCV) (RR: 2.25, p = 0.008). Significant differences were found between patients with and without LBBB in interventricular septal thickness (IVS; by −0.66 mm), membranous septal length (MSL; by −0.9 mm), left ventricular outflow tract (LVOT) diameter (by −0.48 mm), PR interval (by +13.95 ms), and prosthesis implantation depth (by +2.6 mm). Diabetes Mellitus, use of 29‐mm valve or MCV, decreased IVS thickness, shorter MSL, smaller LVOT diameter, increased prosthesis implantation depth, and prolonged PR duration were all associated with an elevated risk of post‐TAVR LBBB. Early identification of these predictors may help reduce the risk of conduction abnormalities after TAVR.
- 30 May 2024
- Published by Springer Nature
- p. 131-135
Preoperative Evaluation
- 30 May 2024
- Published by Springer Nature
- p. 97-104
Assessment of Patients with Suspected Coronary Artery Disease
- 30 May 2024
- Published by Springer Nature
- p. 97-104
Assessment of Patients with Suspected Coronary Artery Disease
- Open Access
- 20 April 2024
- Published by Springer Nature in Current Hypertension Reports
- Vol. 26 (9) , 381-388
Epicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure
Purpose of the Review: Preserved ejection fraction heart failure and obesity frequently coexist. Whether obesity plays a consistent role in the pathogenesis of preserved ejection fraction heart failure is unclear. Accumulation of visceral adiposity underlies the pathogenic aftermaths of obesity. However, visceral adiposity imaging is assessed by computed tomography or magnetic resonance and thus not routinely available. In contrast, epicardial adiposity thickness is assessed by echocardiography and thus routinely available. We review the rationale for assessing epicardial adiposity thickness in patients with preserved ejection fraction heart failure and elevated body mass index. Recent Findings: Body mass index correlates poorly with visceral, and epicardial adiposity. Visceral and epicardial adiposity enlarges as preserved ejection fraction heart failure progresses. Epicardial adiposity may hasten the progression of coronary artery disease and impairs left ventricular sub-endocardial perfusion and diastolic function. Summary: Epicardial adiposity thickness may help monitor the therapeutic response in patients with preserved ejection failure heart failure and elevated body mass index.
- 20 April 2024
- Published by Springer Nature in Current Hypertension Reports
- Vol. 26 (9) , 381-388
Open AccessEpicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure
Purpose of the Review: Preserved ejection fraction heart failure and obesity frequently coexist. Whether obesity plays a consistent role in the pathogenesis of preserved ejection fraction heart failure is unclear. Accumulation of visceral adiposity underlies the pathogenic aftermaths of obesity. However, visceral adiposity imaging is assessed by computed tomography or magnetic resonance and thus not routinely available. In contrast, epicardial adiposity thickness is assessed by echocardiography and thus routinely available. We review the rationale for assessing epicardial adiposity thickness in patients with preserved ejection fraction heart failure and elevated body mass index. Recent Findings: Body mass index correlates poorly with visceral, and epicardial adiposity. Visceral and epicardial adiposity enlarges as preserved ejection fraction heart failure progresses. Epicardial adiposity may hasten the progression of coronary artery disease and impairs left ventricular sub-endocardial perfusion and diastolic function. Summary: Epicardial adiposity thickness may help monitor the therapeutic response in patients with preserved ejection failure heart failure and elevated body mass index.
- Open Access
- 8 May 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3341
Obesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling
Owing to the overwhelming obesity epidemic, preserved ejection fraction heart failure commonly ensues in patients with severe obesity and the obese phenotype of preserved ejection fraction heart failure is now commonplace in clinical practice. Severe obesity and preserved ejection fraction heart failure share congruent cardiovascular, immune, and renal derangements that make it difficult to ascertain whether the obese phenotype of preserved ejection fraction heart failure is the convergence of two highly prevalent conditions or severe obesity enables the development and progression of the syndrome of preserved ejection fraction heart failure. Nevertheless, the obese phenotype of preserved ejection fraction heart failure provides a unique opportunity to assess whether sustained and sizeable loss of excess body weight via metabolic bariatric surgery reverses the concentric left ventricular remodeling that patients with preserved ejection fraction heart failure commonly display.
- 8 May 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3341
Open AccessObesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling
Owing to the overwhelming obesity epidemic, preserved ejection fraction heart failure commonly ensues in patients with severe obesity and the obese phenotype of preserved ejection fraction heart failure is now commonplace in clinical practice. Severe obesity and preserved ejection fraction heart failure share congruent cardiovascular, immune, and renal derangements that make it difficult to ascertain whether the obese phenotype of preserved ejection fraction heart failure is the convergence of two highly prevalent conditions or severe obesity enables the development and progression of the syndrome of preserved ejection fraction heart failure. Nevertheless, the obese phenotype of preserved ejection fraction heart failure provides a unique opportunity to assess whether sustained and sizeable loss of excess body weight via metabolic bariatric surgery reverses the concentric left ventricular remodeling that patients with preserved ejection fraction heart failure commonly display.
- 28 December 2018
- Published by Wiley in Echocardiography
- Vol. 36 (2) , 406-410
Quadricuspid aortic valve: Case series and review of literature
A quadricuspid aortic valve is an uncommon valve lesion. Its physical manifestations vary, and it may be associated with other cardiac lesions. Echocardiography is the imaging modality of choice, with computerized tomography or cardiac magnetic resonance imaging being utilized as adjunctive imaging modalities in certain cases. Herein, we present a case series of three patients with this valvular lesion treated at our institution, as well as a contemporary review of the literature.
- 28 December 2018
- Published by Wiley in Echocardiography
- Vol. 36 (2) , 406-410
Quadricuspid aortic valve: Case series and review of literature
A quadricuspid aortic valve is an uncommon valve lesion. Its physical manifestations vary, and it may be associated with other cardiac lesions. Echocardiography is the imaging modality of choice, with computerized tomography or cardiac magnetic resonance imaging being utilized as adjunctive imaging modalities in certain cases. Herein, we present a case series of three patients with this valvular lesion treated at our institution, as well as a contemporary review of the literature.
- Open Access
- 1 March 2017
- Published by Instituto Mexicano del Seguro Social in Revista Colombiana de Cardiología
- Vol. 24 (2) , 169-175
Efectos de un programa de ejercicio físico de 12 semanas en sujetos con revascularización coronaria o postangioplastia transluminal percutánea
ResumenObjetivoDeterminar los efectos de un programa de ejercicio físico sobre las características antropométricas y la capacidad funcional postcirugía de revascularización coronaria o postangioplastia coronaria transluminal percutánea.MétodosEstudio clínico no controlado, de antes y después, en 49 pacientes postcirugía de revascularización coronaria o angioplastia coronaria percutánea. El índice de masa corporal, perímetro abdominal, índice de cintura cadera, perímetro de la cadera y la capacidad cardiorrespiratoria a través de la caminata de los seis minutos fueron evaluados antes y al finalizar el programa de ejercicio físico. Este estuvo conformado por ejercicios aeróbicos continuos, de resistencia muscular, equilibrio y coordinación, durante 3 días a la semana, durante 12 semanas.ResultadosCon relación al perímetro abdominal en las mujeres cambió de 91,4cm a 88,4cm (p=0,003) y en los hombres de 93,6cm a 89,8 (p=0,000). Se logró un incremento significativo de la distancia caminada de 330 a 436 metros (p=0,000); del consumo energético de 3,4 a 4,1 MET (p=0,000); y la máxima capacidad de absorber, transportar y consumir el oxígeno, de 12 a 14ml/Kg/min.ConclusionesEl programa de ejercicio físico que fue utilizado en este estudio, pudo en todos los sujetos incrementar la capacidad cardiorrespiratoria y la tolerancia al ejercicio, y disminuir el perímetro abdominal. Los efectos benéficos obtenidos cambian el pronóstico de la enfermedad coronaria y disminuyen los factores de riesgo metabólicos.AbstractMotivationTo determine the effects of a physical exercise program in the anthropometric characteristics and postsurgical functional capacity after coronary revascularization or percutaneous transluminal coronary angioplasty.MethodsUncontrolled clinical before and after study, in 49 patients who has undergone coronary revascularization or percutaneous transluminal coronary angioplasty. Body mass index, abdominal girth, waist-to-hip ratio, hip perimeter and cardiorespiratory function were assessed by means of the six-minute walk test before and after the physical exercise program. It consisted of continuous aerobic, muscle resistance, balance and coordination exercises three times a week during a total of 12 weeks.ResultsAbdominal girth changed from 91.4cm to 88.4cm (p=0.003) in women and from 93.6cm to 89.8cm (p=0.000). A significant increase of the walked distance was achieved, from 330 to 436 meters (p=0.000); energy use from 3.4 to 4.1 MET (p=0.000); and maximum capacity of absorbing, transporting and consuming oxygen, from 12 to 14ml/Kg/min.ConclusionThe physical activity program used in this study contributed to an increase in all participants of the cardiorespiratory function and exercise tolerance, and to a decrease in abdominal girth. These beneficial effects change the prognosis of the coronary disease and reduce the metabolic risk factors
- 1 March 2017
- Published by Instituto Mexicano del Seguro Social in Revista Colombiana de Cardiología
- Vol. 24 (2) , 169-175
Open AccessEfectos de un programa de ejercicio físico de 12 semanas en sujetos con revascularización coronaria o postangioplastia transluminal percutánea
ResumenObjetivoDeterminar los efectos de un programa de ejercicio físico sobre las características antropométricas y la capacidad funcional postcirugía de revascularización coronaria o postangioplastia coronaria transluminal percutánea.MétodosEstudio clínico no controlado, de antes y después, en 49 pacientes postcirugía de revascularización coronaria o angioplastia coronaria percutánea. El índice de masa corporal, perímetro abdominal, índice de cintura cadera, perímetro de la cadera y la capacidad cardiorrespiratoria a través de la caminata de los seis minutos fueron evaluados antes y al finalizar el programa de ejercicio físico. Este estuvo conformado por ejercicios aeróbicos continuos, de resistencia muscular, equilibrio y coordinación, durante 3 días a la semana, durante 12 semanas.ResultadosCon relación al perímetro abdominal en las mujeres cambió de 91,4cm a 88,4cm (p=0,003) y en los hombres de 93,6cm a 89,8 (p=0,000). Se logró un incremento significativo de la distancia caminada de 330 a 436 metros (p=0,000); del consumo energético de 3,4 a 4,1 MET (p=0,000); y la máxima capacidad de absorber, transportar y consumir el oxígeno, de 12 a 14ml/Kg/min.ConclusionesEl programa de ejercicio físico que fue utilizado en este estudio, pudo en todos los sujetos incrementar la capacidad cardiorrespiratoria y la tolerancia al ejercicio, y disminuir el perímetro abdominal. Los efectos benéficos obtenidos cambian el pronóstico de la enfermedad coronaria y disminuyen los factores de riesgo metabólicos.AbstractMotivationTo determine the effects of a physical exercise program in the anthropometric characteristics and postsurgical functional capacity after coronary revascularization or percutaneous transluminal coronary angioplasty.MethodsUncontrolled clinical before and after study, in 49 patients who has undergone coronary revascularization or percutaneous transluminal coronary angioplasty. Body mass index, abdominal girth, waist-to-hip ratio, hip perimeter and cardiorespiratory function were assessed by means of the six-minute walk test before and after the physical exercise program. It consisted of continuous aerobic, muscle resistance, balance and coordination exercises three times a week during a total of 12 weeks.ResultsAbdominal girth changed from 91.4cm to 88.4cm (p=0.003) in women and from 93.6cm to 89.8cm (p=0.000). A significant increase of the walked distance was achieved, from 330 to 436 meters (p=0.000); energy use from 3.4 to 4.1 MET (p=0.000); and maximum capacity of absorbing, transporting and consuming oxygen, from 12 to 14ml/Kg/min.ConclusionThe physical activity program used in this study contributed to an increase in all participants of the cardiorespiratory function and exercise tolerance, and to a decrease in abdominal girth. These beneficial effects change the prognosis of the coronary disease and reduce the metabolic risk factors
- Open Access
- 1 September 2016
- Published by Instituto Mexicano del Seguro Social in Revista Colombiana de Cardiología
- Vol. 23 (5) , 365-374
Prevalencia del síndrome metabólico en hipertensos estadio I
ResumenIntroducción y ObjetivoEn sujetos con hipertensión arterial sistémica recién diagnosticada es importante verificar la existencia de otros factores de riesgo para enfermedad cardiovascular para poder establecer estrategias para su óptimo tratamiento. Conocer cual es la prevalencia del síndrome metabólico en sujetos con hipertensión arterial sistémica estadio 1.MétodosEstudio prospectivo, observacional, transversal, realizado durante un año en Bogotá, Medellín, Cali y Barranquilla en sujetos de ambos géneros, ≥ 18 años y ≤ 60 años con hipertensión arterial sistémica estadio 1 recién diagnosticada y sin tratamiento farmacológico. A todos los sujetos se les verificó la existencia de síndrome metabólico de acuerdo con el reciente consenso de la Federación Internacional de Diabetes, del Instituto Nacional del Corazón, Pulmón y Sangre, de la Asociación Americana del Corazón, de la Federación Mundial del Corazón, de la Sociedad Internacional de Aterosclerosis y de la Asociación Internacional para el Estudio de la Obesidad.ResultadosLa prevalencia promedio de síndrome metabólico en la población total de hipertensos estudiada fue de 16.84%. En Cali fue de 28.8%, en Medellín fue 18.9%, en Barranquilla fue 12.5% y en Bogotá fue 11.4%. Medellín tuvo la más alta prevalencia en hombres (14.7%) y Cali la mas alta en mujeres (15.2%).ConclusionesEn los sujetos con hipertensión arterial sistémica de reciente diagnóstico se recomienda realizar una búsqueda sistemática del síndrome metabólico. En las ciudades estudiadas de Colombia existió gran variabilidad en la prevalencia del síndrome metabólico encontrada. Se requieren estudios para conocer en otras ciudades de Colombia cual es la prevalencia real del síndrome metabólico en sujetos con hipertensión arterial sistémica en el pais e implementar estrategias educativas para minimizar esta.AbstractIntroduction and motivationIt is important for recently diagnosed systemic hypertension (HPB) individuals to verify the existence of other cardiovascular risk factors, in order to establish optimal treatment strategies. Knowing the prevalence of metabolic syndrome (MS) in patients with stage 1 HBP.MethodsProspective, observational, cross-sectional study conducted over one year in Bogotá, Medellin, Cali and Barranquilla in individuals of both genders, ≥ 18 and ≤ 60 years old with recently diagnosed stage 1 HBP and without drug therapy. Presence of MS was verified for all subjects according to recent consensus of the International Diabetes Federation, the National Heart, Lung and Blood Institute, the American Heart Association, the World Heart Federation, the International Atherosclerosis Society and the International Association for the Study of Obesity.ResultsAverage prevalence of MS in the total population of hypertensive patients was of 16.84%. In Cali it was of 28.8%, in Medellin of 18.9%, in Barranquilla of 12.5% and in Bogotá of 11.4%. Medellin showed the highest prevalence in men (14.7%) and Cali in women (15.2%).ConclusionsIt is recommended to conduct a systematic search for MS in patients who have recently been diagnosed with HBP. Prevalence among MS in the studies Colombian cities varied greatly. More studies are required to find out about the real prevalence of MS in patients with HBP in other Colombian cities and to implement educational studies to minimise its impact
- 1 September 2016
- Published by Instituto Mexicano del Seguro Social in Revista Colombiana de Cardiología
- Vol. 23 (5) , 365-374
Open AccessPrevalencia del síndrome metabólico en hipertensos estadio I
ResumenIntroducción y ObjetivoEn sujetos con hipertensión arterial sistémica recién diagnosticada es importante verificar la existencia de otros factores de riesgo para enfermedad cardiovascular para poder establecer estrategias para su óptimo tratamiento. Conocer cual es la prevalencia del síndrome metabólico en sujetos con hipertensión arterial sistémica estadio 1.MétodosEstudio prospectivo, observacional, transversal, realizado durante un año en Bogotá, Medellín, Cali y Barranquilla en sujetos de ambos géneros, ≥ 18 años y ≤ 60 años con hipertensión arterial sistémica estadio 1 recién diagnosticada y sin tratamiento farmacológico. A todos los sujetos se les verificó la existencia de síndrome metabólico de acuerdo con el reciente consenso de la Federación Internacional de Diabetes, del Instituto Nacional del Corazón, Pulmón y Sangre, de la Asociación Americana del Corazón, de la Federación Mundial del Corazón, de la Sociedad Internacional de Aterosclerosis y de la Asociación Internacional para el Estudio de la Obesidad.ResultadosLa prevalencia promedio de síndrome metabólico en la población total de hipertensos estudiada fue de 16.84%. En Cali fue de 28.8%, en Medellín fue 18.9%, en Barranquilla fue 12.5% y en Bogotá fue 11.4%. Medellín tuvo la más alta prevalencia en hombres (14.7%) y Cali la mas alta en mujeres (15.2%).ConclusionesEn los sujetos con hipertensión arterial sistémica de reciente diagnóstico se recomienda realizar una búsqueda sistemática del síndrome metabólico. En las ciudades estudiadas de Colombia existió gran variabilidad en la prevalencia del síndrome metabólico encontrada. Se requieren estudios para conocer en otras ciudades de Colombia cual es la prevalencia real del síndrome metabólico en sujetos con hipertensión arterial sistémica en el pais e implementar estrategias educativas para minimizar esta.AbstractIntroduction and motivationIt is important for recently diagnosed systemic hypertension (HPB) individuals to verify the existence of other cardiovascular risk factors, in order to establish optimal treatment strategies. Knowing the prevalence of metabolic syndrome (MS) in patients with stage 1 HBP.MethodsProspective, observational, cross-sectional study conducted over one year in Bogotá, Medellin, Cali and Barranquilla in individuals of both genders, ≥ 18 and ≤ 60 years old with recently diagnosed stage 1 HBP and without drug therapy. Presence of MS was verified for all subjects according to recent consensus of the International Diabetes Federation, the National Heart, Lung and Blood Institute, the American Heart Association, the World Heart Federation, the International Atherosclerosis Society and the International Association for the Study of Obesity.ResultsAverage prevalence of MS in the total population of hypertensive patients was of 16.84%. In Cali it was of 28.8%, in Medellin of 18.9%, in Barranquilla of 12.5% and in Bogotá of 11.4%. Medellin showed the highest prevalence in men (14.7%) and Cali in women (15.2%).ConclusionsIt is recommended to conduct a systematic search for MS in patients who have recently been diagnosed with HBP. Prevalence among MS in the studies Colombian cities varied greatly. More studies are required to find out about the real prevalence of MS in patients with HBP in other Colombian cities and to implement educational studies to minimise its impact
- Open Access
- 1 May 2013
- Published by Instituto Mexicano del Seguro Social in Revista Colombiana de Cardiología
- Vol. 20 (3) , 149-153
Efectos cardiovasculares de fingolimod en el tratamiento de la esclerosis múltiple
Fingolimod es un medicamento modificador de la enfermedad para pacientes con esclerosis múltiple de tipo recaída remisión; la molécula es un análogo de esfingosina fosfato que debido a su mecanismo de acción, produce en 0,5% de los pacientes, una disminución de la frecuencia cardíaca durante la administración de la primera dosis y un aumento leve de la presión arterial al segundo mes de tratamiento. En este articulo se revisan los mecanismos celulares por los cuales fingolimod causa estos eventos y se reportan recomendaciones de seguridad basados en la US Food and Drug Administration (FDA) para el inicio de pacientes en tratamiento con este medicamento.Fingolimod is a disease modifying drug for patients with relapse remitting multiple sclerosis (RRMS). The molecule is a sphingosine phosfate analog that because of its mechanism of action causes a decrease in heart rate during the administration of the first dosis and a slight increase in blood pressure in the second month of treatment in 0.5% of patients. We review in this article the cellular mechanisms by which fingolimod causes these events and report safety recommendations based on US Food and Drug Administration (FDA) for initiating treatment with this drug
- 1 May 2013
- Published by Instituto Mexicano del Seguro Social in Revista Colombiana de Cardiología
- Vol. 20 (3) , 149-153
Open AccessEfectos cardiovasculares de fingolimod en el tratamiento de la esclerosis múltiple
Fingolimod es un medicamento modificador de la enfermedad para pacientes con esclerosis múltiple de tipo recaída remisión; la molécula es un análogo de esfingosina fosfato que debido a su mecanismo de acción, produce en 0,5% de los pacientes, una disminución de la frecuencia cardíaca durante la administración de la primera dosis y un aumento leve de la presión arterial al segundo mes de tratamiento. En este articulo se revisan los mecanismos celulares por los cuales fingolimod causa estos eventos y se reportan recomendaciones de seguridad basados en la US Food and Drug Administration (FDA) para el inicio de pacientes en tratamiento con este medicamento.Fingolimod is a disease modifying drug for patients with relapse remitting multiple sclerosis (RRMS). The molecule is a sphingosine phosfate analog that because of its mechanism of action causes a decrease in heart rate during the administration of the first dosis and a slight increase in blood pressure in the second month of treatment in 0.5% of patients. We review in this article the cellular mechanisms by which fingolimod causes these events and report safety recommendations based on US Food and Drug Administration (FDA) for initiating treatment with this drug